IceCure Medical to Report 2025 Full Year Financial and Operating Results on March 17, 2026
Rhea-AI Summary
IceCure Medical (Nasdaq: ICCM) will report full year financial and operating results for the twelve months ended December 31, 2025 before the Nasdaq opens on March 17, 2026. A conference call and live webcast to discuss results and corporate developments will follow at 11:00 a.m. EDT on the same day.
Conference call dial-ins and a live webcast link are provided; a recording will be available on the company's investor website.
Positive
- None.
Negative
- None.
News Market Reaction – ICCM
In the Mar 10 session, ICCM gained 0.26%, reflecting a mild positive market reaction. Argus tracked a peak move of +8.6% during that session. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 12 | Earnings date set | Neutral | +2.5% | Company scheduled Q3 2025 results release and investor conference call. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Historical earnings date communication for ICCM was followed by a modest positive move around the announcement.
Recent same-tag history shows ICCM previously announced an earnings date on November 12, 2025 for Q3 2025 results, with shares moving +2.48% over the next 24 hours. That prior event also paired the date disclosure with details of a conference call and webcast. Today’s announcement similarly schedules the release of full-year 2025 results and a call on March 17, 2026, indicating continued transparency around financial reporting and investor communications.
Key Terms
cryoablation medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference call & webcast info:
Tuesday, March 17, 2026, at 11:00 am EDT
US: 1-888-407-2553
A live webcast will be available at: https://www.veidan-conferencing.com/icecure-investors
A recording of the webcast will be available at: ir.icecure-medical.com
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in
Forward Looking Statement
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements in this press release when it discusses: the timing for announcing its 2025 full year financial and operating results and related conference call. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2024 filed with the
IR Contact:
Email: investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914
Logo - https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/icecure-medical-to-report-2025-full-year-financial-and-operating-results-on-march-17-2026-302709431.html
SOURCE IceCure Medical